img

Global and United States Gene Therapy for Neurodegenerative Diseases Market Report & Forecast 2024-2034

Published on: 2024-01-04 | No of Pages : 400 | Industry : Medical

Publisher : MRA | Format : PDF

Global and United States Gene Therapy for Neurodegenerative Diseases Market Report & Forecast 2024-2034

Market Analysis and InsightsGlobal and United States Gene Therapy for Neurodegenerative Diseases Market
This report focuses on global and United States Gene Therapy for Neurodegenerative Diseases market, also covers the segmentation data of other regions in regional level and county level.
The global Gene Therapy for Neurodegenerative Diseases revenue was US$ million in 2022 and is forecast to a readjusted size of US$ million by 2033 with a CAGR of % during the review period (2023-2033).
In United States the Gene Therapy for Neurodegenerative Diseases revenue is expected to grow from US$ million in 2022 to US$ million by 2033, at a CAGR of % during the forecast period 2023-2033.
The global key players of Gene Therapy for Neurodegenerative Diseases include Voyager Therapeutics, Uniqure N.V., Axovant Gene Therapies, Novartis Ag, Amicus Therapeutics, Regenxbio Inc., Sarepta Therapeutics, Gensight Biologics and Krystal Biotech, etc. The global five biggest players hold a share of % in 2022.
Global Gene Therapy for Neurodegenerative Diseases Scope and Market Size
Gene Therapy for Neurodegenerative Diseases market is segmented in regional and country level, by players, by Type and by Application. Companies, stakeholders, and other participants in the global Gene Therapy for Neurodegenerative Diseases market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by Type and by Application for the period 2018-2033.
For United States market, this report focuses on the Gene Therapy for Neurodegenerative Diseases market size by players, by Type and by Application, for the period 2018-2033. The key players include the global and local players, which play important roles in United States.



By Company


Voyager Therapeutics
Uniqure N.V.
Axovant Gene Therapies
Novartis Ag
Amicus Therapeutics
Regenxbio Inc.
Sarepta Therapeutics
Gensight Biologics
Krystal Biotech
Avexis
Segment by Type
Gene Replacement Therapy
Gene Silencing Therapy
Gene Editing Therapy
Enzyme Replacement Therapy

Segment by Application


Hospitals and Clinics
Research Institutions
Biotechnology Companies
Others
By Region
Americas
United States
Canada
Mexico
Brazil
China
APAC (excluding China)
Japan
South Korea
China Taiwan
ASEAN
India
EMEA
Europe
Middle East
Africa

Chapter Introduction


Chapter 1Introduces Gene Therapy for Neurodegenerative Diseases definition, global market size, United States market size, United States percentage in global market. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 2Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 3Provides the analysis of various market segments by application, covering the revenue and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 4Detailed analysis of Gene Therapy for Neurodegenerative Diseases companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger and acquisition information, etc.
Chapter 5Revenue of Gene Therapy for Neurodegenerative Diseases in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 6Americas by type, by application and by country revenue for each segment.
Chapter 7EMEA by type, by application and by region, revenue for each segment.
Chapter 8China by type, by application revenue for each segment.
Chapter 9APAC (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Gene Therapy for Neurodegenerative Diseases revenue, gross margin and recent development, etc.
Chapter 11Analyst's Viewpoints/Conclusions

Table of Content

1 Study Coverage
1.1 Gene Therapy for Neurodegenerative Diseases Product Introduction
1.2 Global Gene Therapy for Neurodegenerative Diseases Outlook 2018 VS 2022 VS 2033
1.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size for the Year 2018-2033
1.2.2 United States Gene Therapy for Neurodegenerative Diseases Market Size for the Year 2018-2033
1.3 Gene Therapy for Neurodegenerative Diseases Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.3.1 The Market Share of United States Gene Therapy for Neurodegenerative Diseases in Global, 2018 VS 2022 VS 2033
1.3.2 The Growth Rate of Gene Therapy for Neurodegenerative Diseases Market Size, United States VS Global, 2018 VS 2022 VS 2033
1.4 Gene Therapy for Neurodegenerative Diseases Market Dynamics
1.4.1 Gene Therapy for Neurodegenerative Diseases Industry Trends
1.4.2 Gene Therapy for Neurodegenerative Diseases Market Drivers
1.4.3 Gene Therapy for Neurodegenerative Diseases Market Challenges
1.4.4 Gene Therapy for Neurodegenerative Diseases Market Restraints
1.5 Assumptions and Limitations
1.6 Study Objectives
1.7 Years Considered
2 Gene Therapy for Neurodegenerative Diseases by Type
2.1 Gene Therapy for Neurodegenerative Diseases Market Segment by Type
2.1.1 Gene Replacement Therapy
2.1.2 Gene Silencing Therapy
2.1.3 Gene Editing Therapy
2.1.4 Enzyme Replacement Therapy
2.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018, 2022 & 2033)
2.3 Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2033)
2.4 United States Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018, 2022 & 2033)
2.5 United States Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2033)
3 Gene Therapy for Neurodegenerative Diseases by Application
3.1 Gene Therapy for Neurodegenerative Diseases Market Segment by Application
3.1.1 Hospitals and Clinics
3.1.2 Research Institutions
3.1.3 Biotechnology Companies
3.1.4 Others
3.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018, 2022 & 2033)
3.3 Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2033)
3.4 United States Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018, 2022 & 2033)
3.5 United States Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2033)
4 Global Gene Therapy for Neurodegenerative Diseases Competitor Landscape by Company
4.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Company
4.1.1 Global Key Companies of Gene Therapy for Neurodegenerative Diseases, Ranked by Revenue (2022)
4.1.2 Global Gene Therapy for Neurodegenerative Diseases Revenue by Player (2018-2023)
4.2 Global Gene Therapy for Neurodegenerative Diseases Concentration Ratio (CR)
4.2.1 Gene Therapy for Neurodegenerative Diseases Market Concentration Ratio (CR) (2018-2023)
4.2.2 Global Top 5 and Top 10 Largest Companies of Gene Therapy for Neurodegenerative Diseases in 2022
4.2.3 Global Gene Therapy for Neurodegenerative Diseases Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Key Players of Gene Therapy for Neurodegenerative Diseases Head office and Area Served
4.4 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
4.5 Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
4.6 Companies Mergers & Acquisitions, Expansion Plans
4.7 United States Gene Therapy for Neurodegenerative Diseases Market Size by Company
4.7.1 Key Players of Gene Therapy for Neurodegenerative Diseases in United States, Ranked by Revenue (2022)
4.7.2 United States Gene Therapy for Neurodegenerative Diseases Revenue by Players (2021, 2022 & 2023)
5 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region
5.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018 VS 2022 VS 2033
5.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2033)
5.2.1 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region: 2018-2023
5.2.2 Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033)
6 Americas
6.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth 2018-2033
6.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type
6.2.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
6.2.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
6.2.3 Americas Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
6.3 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application
6.3.1 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
6.3.2 Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
6.3.3 Americas Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
6.4 Americas Gene Therapy for Neurodegenerative Diseases Market Facts & Figures by Country (2018, 2022 & 2033)
6.4.1 United States
6.4.2 Canada
6.4.3 Mexico
6.4.4 Brazil
7 EMEA
7.1 EMEA Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth 2018-2033
7.2 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Type
7.2.1 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
7.2.2 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
7.2.3 EMEA Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
7.3 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Application
7.3.1 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
7.3.2 EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
7.3.3 EMEA Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
7.4 EMEA Gene Therapy for Neurodegenerative Diseases Market Facts & Figures by Country (2018, 2022 & 2033)
7.4.1 Europe
7.4.2 Middle East
7.4.3 Africa
8 China
8.1 China Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth 2018-2033
8.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Type
8.2.1 China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
8.2.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
8.2.3 China Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
8.3 China Gene Therapy for Neurodegenerative Diseases Market Size by Application
8.3.1 China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
8.3.2 China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
8.3.3 China Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
9 APAC (excluding China)
9.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size YoY Growth 2018-2033
9.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type
9.2.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023)
9.2.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033)
9.2.3 APAC Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
9.3 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application
9.3.1 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023)
9.3.2 APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033)
9.3.3 APAC Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
9.4 APAC Gene Therapy for Neurodegenerative Diseases Market Facts & Figures by Country (2018, 2022 & 2033)
9.4.1 Japan
9.4.2 South Korea
9.4.3 China Taiwan
9.4.4 Southeast Asia
9.4.5 India
10 Key Players Profiles
10.1 Voyager Therapeutics
10.1.1 Voyager Therapeutics Company Details
10.1.2 Voyager Therapeutics Business Overview
10.1.3 Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
10.1.4 Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.1.5 Voyager Therapeutics Recent Development
10.2 Uniqure N.V.
10.2.1 Uniqure N.V. Company Details
10.2.2 Uniqure N.V. Business Overview
10.2.3 Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Introduction
10.2.4 Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.2.5 Uniqure N.V. Recent Development
10.3 Axovant Gene Therapies
10.3.1 Axovant Gene Therapies Company Details
10.3.2 Axovant Gene Therapies Business Overview
10.3.3 Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Introduction
10.3.4 Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.3.5 Axovant Gene Therapies Recent Development
10.4 Novartis Ag
10.4.1 Novartis Ag Company Details
10.4.2 Novartis Ag Business Overview
10.4.3 Novartis Ag Gene Therapy for Neurodegenerative Diseases Introduction
10.4.4 Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.4.5 Novartis Ag Recent Development
10.5 Amicus Therapeutics
10.5.1 Amicus Therapeutics Company Details
10.5.2 Amicus Therapeutics Business Overview
10.5.3 Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
10.5.4 Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.5.5 Amicus Therapeutics Recent Development
10.6 Regenxbio Inc.
10.6.1 Regenxbio Inc. Company Details
10.6.2 Regenxbio Inc. Business Overview
10.6.3 Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Introduction
10.6.4 Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.6.5 Regenxbio Inc. Recent Development
10.7 Sarepta Therapeutics
10.7.1 Sarepta Therapeutics Company Details
10.7.2 Sarepta Therapeutics Business Overview
10.7.3 Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Introduction
10.7.4 Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.7.5 Sarepta Therapeutics Recent Development
10.8 Gensight Biologics
10.8.1 Gensight Biologics Company Details
10.8.2 Gensight Biologics Business Overview
10.8.3 Gensight Biologics Gene Therapy for Neurodegenerative Diseases Introduction
10.8.4 Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.8.5 Gensight Biologics Recent Development
10.9 Krystal Biotech
10.9.1 Krystal Biotech Company Details
10.9.2 Krystal Biotech Business Overview
10.9.3 Krystal Biotech Gene Therapy for Neurodegenerative Diseases Introduction
10.9.4 Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.9.5 Krystal Biotech Recent Development
10.10 Avexis
10.10.1 Avexis Company Details
10.10.2 Avexis Business Overview
10.10.3 Avexis Gene Therapy for Neurodegenerative Diseases Introduction
10.10.4 Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
10.10.5 Avexis Recent Development
11 Research Findings and Conclusion
12 Appendix
12.1 Research Methodology
12.1.1 Methodology/Research Approach
12.1.2 Data Source
12.2 Disclaimer
12.3 Author Details

List of Figure

List of Tables
Table 1. Gene Therapy for Neurodegenerative Diseases Market Size United States VS Global, CAGR (2018 VS 2022 VS 2033)
Table 2. Gene Therapy for Neurodegenerative Diseases Market Trends
Table 3. Gene Therapy for Neurodegenerative Diseases Market Drivers
Table 4. Gene Therapy for Neurodegenerative Diseases Market Challenges
Table 5. Gene Therapy for Neurodegenerative Diseases Market Restraints
Table 6. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 7. United States Gene Therapy for Neurodegenerative Diseases Market Size by Type: 2018 VS 2022 VS 2033 (US$ Million)
Table 8. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 9. United States Gene Therapy for Neurodegenerative Diseases Market Size by Application: 2018 VS 2022 VS 2033 (US$ Million)
Table 10. Global Key Companies of Gene Therapy for Neurodegenerative Diseases, Ranked by Revenue (2022) & (US$ Million)
Table 11. Global Gene Therapy for Neurodegenerative Diseases Revenue by Player, (US$ Million), 2018-2023
Table 12. Global Gene Therapy for Neurodegenerative Diseases Revenue Share by Player, 2018-2023
Table 13. Global Gene Therapy for Neurodegenerative Diseases Companies Market Concentration Ratio (CR5 and HHI)
Table 14. Global Gene Therapy for Neurodegenerative Diseases by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Gene Therapy for Neurodegenerative Diseases as of 2022)
Table 15. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Headquarters and Area Served
Table 16. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Product and Application
Table 17. Global Key Players of Gene Therapy for Neurodegenerative Diseases, Date of Enter into This Industry
Table 18. Companies Mergers & Acquisitions, Expansion Plans
Table 19. Key Players of Gene Therapy for Neurodegenerative Diseases in United States, Ranked by Revenue (2022) & (US$ Million)
Table 20. United States Gene Therapy for Neurodegenerative Diseases Revenue by Players, (US$ Million), 2021, 2022 & 2023
Table 21. United States Gene Therapy for Neurodegenerative Diseases Revenue Share by Players, 2021, 2022 & 2023
Table 22. Global Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Region (US$ Million): 2018 VS 2022 VS 2033
Table 23. Global Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 24. Global Gene Therapy for Neurodegenerative Diseases Market Size Forecast by Region (2024-2033) & (US$ Million)
Table 25. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 26. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 27. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 28. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 29. Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 30. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 31. Americas Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 32. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 33. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 34. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 35. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 36. EMEA Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 37. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Country (2018-2023) & (US$ Million)
Table 38. EMEA Gene Therapy for Neurodegenerative Diseases Market Size by Country (2024-2033) & (US$ Million)
Table 39. China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 40. China Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 41. China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 42. China Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 43. China Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 44. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2023) & (US$ Million)
Table 45. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Type (2024-2033) & (US$ Million)
Table 46. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2023) & (US$ Million)
Table 47. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Application (2024-2033) & (US$ Million)
Table 48. APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (CAGR) by Country (US$ Million): 2018 VS 2022 VS 2033
Table 49. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2018-2023) & (US$ Million)
Table 50. APAC Gene Therapy for Neurodegenerative Diseases Market Size by Region (2024-2033) & (US$ Million)
Table 51. Voyager Therapeutics Company Details
Table 52. Voyager Therapeutics Business Overview
Table 53. Voyager Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 54. Voyager Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 55. Voyager Therapeutics Recent Development
Table 56. Uniqure N.V. Company Details
Table 57. Uniqure N.V. Business Overview
Table 58. Uniqure N.V. Gene Therapy for Neurodegenerative Diseases Product
Table 59. Uniqure N.V. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 60. Uniqure N.V. Recent Development
Table 61. Axovant Gene Therapies Company Details
Table 62. Axovant Gene Therapies Business Overview
Table 63. Axovant Gene Therapies Gene Therapy for Neurodegenerative Diseases Product
Table 64. Axovant Gene Therapies Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 65. Axovant Gene Therapies Recent Development
Table 66. Novartis Ag Company Details
Table 67. Novartis Ag Business Overview
Table 68. Novartis Ag Gene Therapy for Neurodegenerative Diseases Product
Table 69. Novartis Ag Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 70. Novartis Ag Recent Development
Table 71. Amicus Therapeutics Company Details
Table 72. Amicus Therapeutics Business Overview
Table 73. Amicus Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 74. Amicus Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 75. Amicus Therapeutics Recent Development
Table 76. Regenxbio Inc. Company Details
Table 77. Regenxbio Inc. Business Overview
Table 78. Regenxbio Inc. Gene Therapy for Neurodegenerative Diseases Product
Table 79. Regenxbio Inc. Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 80. Regenxbio Inc. Recent Development
Table 81. Sarepta Therapeutics Company Details
Table 82. Sarepta Therapeutics Business Overview
Table 83. Sarepta Therapeutics Gene Therapy for Neurodegenerative Diseases Product
Table 84. Sarepta Therapeutics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 85. Sarepta Therapeutics Recent Development
Table 86. Gensight Biologics Company Details
Table 87. Gensight Biologics Business Overview
Table 88. Gensight Biologics Gene Therapy for Neurodegenerative Diseases Product
Table 89. Gensight Biologics Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 90. Gensight Biologics Recent Development
Table 91. Krystal Biotech Company Details
Table 92. Krystal Biotech Business Overview
Table 93. Krystal Biotech Gene Therapy for Neurodegenerative Diseases Product
Table 94. Krystal Biotech Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 95. Krystal Biotech Recent Development
Table 96. Avexis Company Details
Table 97. Avexis Business Overview
Table 98. Avexis Gene Therapy for Neurodegenerative Diseases Product
Table 99. Avexis Revenue in Gene Therapy for Neurodegenerative Diseases Business (2018-2023) & (US$ Million)
Table 100. Avexis Recent Development
Table 101. Research Programs/Design for This Report
Table 102. Key Data Information from Secondary Sources
Table 103. Key Data Information from Primary Sources
List of Figures
Figure 1. Gene Therapy for Neurodegenerative Diseases Product Picture
Figure 2. Global Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 3. Global Gene Therapy for Neurodegenerative Diseases Market Size 2018-2033 (US$ Million)
Figure 4. United States Gene Therapy for Neurodegenerative Diseases Market Size, (US$ Million), 2018 VS 2022 VS 2033
Figure 5. United States Gene Therapy for Neurodegenerative Diseases Market Size 2018-2033 (US$ Million)
Figure 6. United States Gene Therapy for Neurodegenerative Diseases Market Share in Global 2018-2033
Figure 7. Gene Therapy for Neurodegenerative Diseases Report Years Considered
Figure 8. Product Picture of Gene Replacement Therapy
Figure 9. Product Picture of Gene Silencing Therapy
Figure 10. Product Picture of Gene Editing Therapy
Figure 11. Product Picture of Enzyme Replacement Therapy
Figure 12. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type in 2022 & 2033
Figure 13. Global Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2033) & (US$ Million)
Figure 14. Global Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 15. United States Gene Therapy for Neurodegenerative Diseases Market Share by Type in 2022 & 2033
Figure 16. United States Gene Therapy for Neurodegenerative Diseases Market Size by Type (2018-2033) & (US$ Million)
Figure 17. United States Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 18. Product Picture of Hospitals and Clinics
Figure 19. Product Picture of Research Institutions
Figure 20. Product Picture of Biotechnology Companies
Figure 21. Product Picture of Others
Figure 22. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application in 2022 & 2033
Figure 23. Global Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2033) & (US$ Million)
Figure 24. Global Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 25. United States Gene Therapy for Neurodegenerative Diseases Market Share by Application in 2022 & 2033
Figure 26. United States Gene Therapy for Neurodegenerative Diseases Market Size by Application (2018-2033) & (US$ Million)
Figure 27. United States Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 28. The Top 5 and 10 Largest Companies of Gene Therapy for Neurodegenerative Diseases in the World: Market Share by Gene Therapy for Neurodegenerative Diseases Revenue in 2022
Figure 29. Global Gene Therapy for Neurodegenerative Diseases Market Size Market Share by Region: 2018 VS 2022 VS 2033
Figure 30. Global Gene Therapy for Neurodegenerative Diseases Market Share by Region (2018-2033)
Figure 31. Americas Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2033 (US$ Million)
Figure 32. Americas Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 33. Americas Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 34. United States Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 35. Canada Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 36. Mexico Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 37. Brazil Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 38. EMEA Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2033 (US$ Million)
Figure 39. EMEA Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 40. EMEA Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 41. Europe Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 42. Middle East Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 43. Africa Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 44. China Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2033 (US$ Million)
Figure 45. China Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 46. China Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 47. APAC Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate 2018-2033 (US$ Million)
Figure 48. APAC Gene Therapy for Neurodegenerative Diseases Market Share by Type (2018-2033)
Figure 49. APAC Gene Therapy for Neurodegenerative Diseases Market Share by Application (2018-2033)
Figure 50. Japan Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 51. South Korea Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 52. China Taiwan Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 53. Southeast Asia Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 54. India Gene Therapy for Neurodegenerative Diseases Market Size Growth Rate (2018-2033) & (US$ Million)
Figure 55. Voyager Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 56. Uniqure N.V. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 57. Axovant Gene Therapies Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 58. Novartis Ag Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 59. Amicus Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 60. Regenxbio Inc. Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 61. Sarepta Therapeutics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 62. Gensight Biologics Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 63. Krystal Biotech Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 64. Avexis Revenue Growth Rate in Gene Therapy for Neurodegenerative Diseases Business (2018-2023)
Figure 65. Bottom-up and Top-down Approaches for This Report
Figure 66. Data Triangulation
Figure 67. Key Executives Interviewed

Select User License

$4200 Single Licence
$6000 Enterprise Licence
$9100 Corporate Licence
Note : All prices in USD

FAQ'S

User License?

For a single, multi and corporate client license, the report will be available in PDF format. Sample report would be given you in excel format. For more questions please contact:

sales@mraccuracyreports.com

Within 24 to 48 hrs.

You can contact Sales team (sales@mraccuracyreports.com) and they will direct you on email

You can order a report by selecting payment methods, which is bank wire or online payment through any Debit/Credit card, Razor pay or PayPal.

Discounts are available.

Hard Copy

Email

Top Industries